Hinge Health’s (HNGE) Overweight Rating Reiterated at Piper Sandler

Piper Sandler reissued their overweight rating on shares of Hinge Health (NYSE:HNGE) in a research note released on Wednesday, MarketBeat reports. The brokerage currently has a $71.00 price target on the stock, up from their prior price target of $70.00.

A number of other research analysts also recently weighed in on HNGE. Evercore ISI upped their price objective on shares of Hinge Health from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 8th. Morgan Stanley upped their price target on Hinge Health from $57.00 to $67.00 and gave the stock an “overweight” rating in a report on Tuesday, September 23rd. Baird R W upgraded Hinge Health to a “hold” rating in a research report on Friday, September 5th. Canaccord Genuity Group boosted their price objective on Hinge Health from $52.00 to $61.00 and gave the company a “buy” rating in a research report on Wednesday, August 6th. Finally, Citigroup initiated coverage on Hinge Health in a research note on Monday, July 14th. They set an “outperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $59.93.

Hinge Health Stock Up 0.9%

Shares of HNGE stock traded up $0.39 on Wednesday, hitting $44.43. The company had a trading volume of 1,151,351 shares, compared to its average volume of 1,298,235. Hinge Health has a twelve month low of $33.42 and a twelve month high of $62.18. The company’s 50-day simple moving average is $52.43.

Hinge Health (NYSE:HNGE) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.18. The company had revenue of $154.21 million for the quarter, compared to analysts’ expectations of $142.44 million. The company’s quarterly revenue was up 53.3% compared to the same quarter last year. Hinge Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Institutional Investors Weigh In On Hinge Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Hinge Health during the third quarter worth $37,000. Montag A & Associates Inc. purchased a new stake in Hinge Health during the 2nd quarter valued at about $41,000. Jones Financial Companies Lllp grew its stake in Hinge Health by 348.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,120 shares of the company’s stock valued at $54,000 after acquiring an additional 870 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in Hinge Health in the 2nd quarter valued at about $48,000. Finally, Lisanti Capital Growth LLC lifted its position in Hinge Health by 2.0% during the third quarter. Lisanti Capital Growth LLC now owns 60,911 shares of the company’s stock worth $2,990,000 after buying an additional 1,211 shares in the last quarter.

About Hinge Health

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.